281 related articles for article (PubMed ID: 23451796)
21. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
22. Understanding the safety of the new ultra long acting basal insulin.
Ramachandran A; Gupta V; Kesavadev J; Kalra S
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
[TBL] [Abstract][Full Text] [Related]
23. Insulin degludec: overview of a novel ultra long-acting basal insulin.
Gough SC; Harris S; Woo V; Davies M
Diabetes Obes Metab; 2013 Apr; 15(4):301-9. PubMed ID: 23240573
[TBL] [Abstract][Full Text] [Related]
24. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Khunti K; Cos X; Rutten G
Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
[TBL] [Abstract][Full Text] [Related]
25. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
26. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD
Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
Hompesch M; Patel DK; LaSalle JR; Bolli GB
Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
[TBL] [Abstract][Full Text] [Related]
29. Integrating advances in insulin into clinical practice: Overview of current insulin formulations.
Rhinehart AS
J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S4-8. PubMed ID: 24080572
[TBL] [Abstract][Full Text] [Related]
30. Translating structure to clinical properties of an ideal basal insulin.
Unnikrishnan AG; Bantwal G; Sahay RK
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):15-20. PubMed ID: 25330627
[TBL] [Abstract][Full Text] [Related]
31. Insulin degludec: a novel basal insulin analogue.
Goldman-Levine JD; Patel DK; Schnee DM
Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
[TBL] [Abstract][Full Text] [Related]
32. Insulin detemir: a new basal insulin analogue.
Soran H; Younis N
Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
[TBL] [Abstract][Full Text] [Related]
33. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of basal insulins.
Porcellati F; Bolli GB; Fanelli CG
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous insulin: pharmacokinetic variability and glycemic variability.
Guerci B; Sauvanet JP
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S7-4S24. PubMed ID: 16389894
[TBL] [Abstract][Full Text] [Related]
36. Treating to target in type 2 diabetes: the BEGIN trial programme.
Wangnoo SK; Chowdhury S; Rao PV
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
[TBL] [Abstract][Full Text] [Related]
37. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
38. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
Haahr H; Fita EG; Heise T
Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
[TBL] [Abstract][Full Text] [Related]
39. The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
Reid TS; White J; Meneghini L
J Fam Pract; 2019 Jan; 68(1 Suppl):. PubMed ID: 30677105
[TBL] [Abstract][Full Text] [Related]
40. Insulin preparations with prolonged effect.
Owens DR
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
